생화학분자생물학회

	Yong-Soo Bae ( ysbae04@skku.edu )
	2022.-present	Distinguished Professor, Sungkyunkwan University,
	2004-2022	Professor, Dept.. Biological Sciences, Sungkyunkwan University,
	1993-2003	Ass/Asoc/Full Prof. Dept Microbiology, Hannam University
	1991-1993	Post-Dr Fellow, Dept. Pathology, Harvard Medical School, USA
	1986-1990	Ph.D, Infectious Diseases, Medical School, University of Calgary, Canada
	1977-1983	BS/MS, Dept. Microbiology, Seoul National University

IL-33 and IL-33-derived DC-based tumor immunotherapy

Intreleukin-33 (IL-33), a member of the IL-1 family, is a cytokine released in response to tissue damage and is recognized as an alarmin. The multifaceted roles of IL-33 in tumor progression have sparked controversy within the scientific community. However, most findings can be generally categorized that endogenous IL-33 demonstrates a pro-tumor effect, while exogenous IL-33 often exhibits an anti-tumor effect in most cases. This review covers general characteristics of IL-33, and its effects on tumor growth with detailed immunological mechanisms in association with dendritic cells (DCs). Notably, DCs possess the capability for antigen uptake, processing, and presentation to CD8+ T cells, positioning them as a professional antigen presenting cells. Recent findings from our research highlight the direct association between the tumor-suppressive effects of exogenous IL-33 and a novel subset of highly immunogenic cDC1s. Exogeneous IL-33 induce the development of these highly immunogenic cDC1s through the activation of other ST2+ immune cells, both in vivo and in vitro. Recognizing the pivotal role of the immunogenicity of DC vaccine in DC-based tumor immunotherapy, we propose compelling methods to enhance this immunogenicity through the integration of IL-33 and the promotion of highly immunogenic DC generation.

Exp.Mol.Med 2024, June 3, vol.56 (6), pp.1340-1347
https://doi.org/10.1038/s12276-024-01249-4